as follows: MRC dyspnoea score from 0-3 to 4-5; 6-min walking distance (6MWD)(% pred), FVC (% pred) or DLCO (% pred) decline >5%; composite physiologic index (CPI) increase >5, A-aO 2 increase >5 mmHg.
To confirm the results, the independent, significant predictors were tested in a retrospective cohort of 68 subjects diagnosed with IPF at Pulmonary Unit, University of Siena.
Follow-up data for at least 3 years after diagnosis were retrospectively collected.
Subjects
The initial diagnosis of IPF was based on the 2000 ATS/ERS criteria [1] : insidious onset of otherwise unexplained dyspnoea on exertion; persistent crackles on auscultation; evidence of pulmonary fibrosis at HRCT scan, consisting of a honeycomb pattern with basal and peripheral reticular opacities and traction bronchiectasis, in the absence of peribronchovascular nodules, micronodules, isolated cysts and consolidation; abnormal PFTs, including evidence of lung restriction, hypoxemia and decreased DLCO, in the absence of other causes of pulmonary fibrosis; BAL or transbronchial biopsy showing no features incompatible with a diagnosis of IPF; age ≥50 years; duration of illness >3 months. In all cases, the extent of ground-glass opacities was less than the extent of the honeycomb lung.
The presence of collagen vascular diseases was excluded in all patients through detailed history, clinical examination and the following serum tests: P-ANCA, C-ANCA, ENA, antinucleus, anti-mitochondrion and anti-DNA antibodies tests, and serum tests for rheumatoid factor, angiotensin-converting enzyme and cryoglobulins. Subjects with primary cardiac diseases, peripheral vascular disease, anemia, and disorders of the chest wall or pleura were excluded from the study. At the time of diagnosis, all patients were in a stable clinical and functional state, without clinical, radiographic or electrocardiographic signs of heart failure or acute inflammation.
The onset of symptoms was defined based on patient's recollection of the first appearance of cough throughout the day or of dyspnoea walking up inclines.
In the prospective cohort, during the study period, 13 subjects were treated with prednisone, azathioprine and N-acetylcysteine, 24 subjects with prednisone and Nacetylcysteine, 17 subjects with prednisone alone, and 16 subjects had no specific treatment.
In the retrospective cohort, 50 subjects were treated with Prednisone, Azathioprine and Nacetylcysteine, 4 subjects with Prednisone and N-acetylcysteine, 8 subjects with Prednisone alone, and 6 had no specific treatment.
Lung biopsy
Lung biopsies were obtained by VATS. The surgeon was asked to biopsy areas involved with ground glass opacity and/or reticular opacity. A clinical pathologist suggested the diagnosis of UIP.
Pulmonary function tests
Pulmonary function tests (PFTs) were performed according to the ATS guidelines [2] .
Patients were studied seated upright in a comfortable chair, with a nose clip on and care was taken to keep the neck at a fixed neutral position. All manoeuvres were initiated from resting % pred) [3] . The CPI provides an estimate of disease extent and takes into account the confounding factor of concomitant emphysema.
The alveolar-arterial gradient for O 2 (AaO 2 ) was obtained in the seated position, at rest for at least 30 min.
Dyspnoea evaluation
The severity of chronic dyspnoea, defined as 'the unpleasant sensation of labored or difficult breathing', was rated according to the modified MRC score [4] . Verbal descriptors of MRC scale start from 0 (not troubled by dyspnoea) to a maximum value of 5 (dyspnoea for minimal effort). The MRC score was administered by a physician.
6-min walking test
The 6-MWT was performed according to the ATS recommendations [5] , along a flat indoor corridor, with continuous monitoring of oxygen arterial saturation with pulse oximetry, heart rate and breathing frequency. If the resting saturation was less than 88% in room air, the patients were considered not eligible for room air 6-MWT. During the test, patients were asked to walk as fast as possible and were allowed to slow down or to stop as necessary. If the patient exhibited an oxygen saturation <88%, the study was repeated with supplemental oxygen. During the 6-MWT, patients undergoing long-term oxygen treatment used the same inspired O 2 concentration as they normally used during their daily activities. At the end of the test, the covered distance in meters was calculated. The 6-MWD values were then expressed as % pred., using the equations of Enright and Sherrill [6] .
High-resolution CT scanning
HRCT was performed with a single breath-hold in the supine position, without intravenous injection of contrast material and using a filter for the osseous tissue. Onemillimeter-thick sections were taken, with a 1-second scan time and an interval of 10 mm in the apex-basis scans, including both lungs in field of view.
Three radiologists were asked to independently evaluate the HRCT scans taken at the time of diagnosis as either: consistent with UIP pattern; possible UIP pattern; or incosistent with UIP pattern. The inter-observer variability among the three core radiologists fell into the limits established by large reports (Suppl. Table 2 ) [7, 8] .
The total extent of fibrosis at time of diagnosis was evaluated with a visual score, as previously described (9-11). The evaluation was based on a 5-point scale (0 = absence of lesions, 1, 2, 3, 4 = extent of lesions, respectively, <25%, 25-50%, 50-75%, >75%). The scores assigned for each scan and each hemithorax were summed, and a final value, expressed as a pixel-index, were obtained with the following formula: real score = 100/maximum predicted value (equivalent to 8 times the number of scans performed). The extent of fibrosis, expressed as a percentage of the total lung volume with a 5% approximation, was separately calculated by the 3 core radiologists, who had no knowledge of the clinical and functional findings. The final score (HRCT disease extent) was obtained as a mean of the 3 observations. Concomitant emphysema was defined as permeative destruction, without visible walls.
Bronchoalveolar lavage
As a part of the initial assessment, BAL was obtained in 27 subjects of the final cohort.
BAL was obtained upon clinician's judgment, but it was not sistematically performed. An aliquot of 50 ml of sterile normal saline was instilled through the bronchoscope into the middle bronchus and retrieved by mechanical suction. This was repeated once. The fluid was processed by using the standard tecnique previously described [12] .
Acute exacerbations
Acute exacerbations (AE) were defined based on the criteria described by Akira et al. 
Statistical analysis
Values are expressed as mean±SD. The Kolmogorov-Smirnov test was used for distribution analysis. Weighted k coefficients were used to assess the level of interobserver agreement among radiologists. Comparisons were made with the Student's t unpaired test or with the Mann-Whitney test, where appropriate. The correlation between CPI and HRCT fibrosis score was examined with the Spearman's rank correlation. The optimal cut-off value for different variables to detect mortality or acute exacerbation was assessed using the receiver operating characteristic (ROC) analysis. Survival was evaluated using Kaplan-Meier survival curves and the log-rank test. Cox proportional hazards regression analysis was used to identify significant variables predicting survival status or acute exacerbation. The results were summarised as hazard ratios, representing the relative risk of dying as a result of a specific characteristic during the observation period. Variables selected via univariate analysis (p<0.05) were evaluated in the multivariate Cox regression analysis. p values <0.05 were regarded as significant. JMP (SAS Institute Inc., Cary, N.C.), GraphPad (MacKiev Software, San Diego, CA) and MedCalc (MedCalc Software, Mariakerke, Belgium) softwares were used.
SUPPLEMENTAL RESULTS
No significant differences in terms of age, smoking history and time to diagnosis were observed between survivors and non-survivors (Table 2) .
Univariate analysis and Kaplan-Meier curves confirmed that several variables at the time of diagnosis were significant predictors of 3-year survival: BMI, MRCDS, 6MWD (% pred), desaturation at the 6MWT, A-aO 2 , FVC, DLCO, CPI, HRCT disease extent and BAL-TCC (Table 3A , Suppl. Figure 2A-L) . Age and time to diagnosis did not predict mortality risk (Table   3A) . Patients with CE had a tendency (p=0.063) towards worse survival in the long term (starting about 18 months after diagnosis)(Suppl. Figure 2F ).
6-month worsening of MRCDS (from 0-3 to 4-5), 6MWD (≥5% pred decline), FVC (≥5% pred decline) and CPI (≥5 increase) were significant predictors of risk of mortality in the next 30 months (Suppl. Figure 3A- C and E), while worsening of DLCO (≥5% pred decline) and A-aO 2 (≥5 increase) were not (Suppl. Figure 3D and F) . A 6-month worsening of 6MWD (m), defined as a decline ≥24 m (18), was not significantly associated with increased mortality (p=0.25).
In the retrospective coort since MRCDS was not available, for the purpose of 3-year survival prediction, risk groups were defined as follows (Risk stratificatiOn ScorE -ROSE): low risk (n=15): 6MWD>72% pred and CPI≤41; intermediate risk (n=36): 6MWD≤72% or CPI>41; high risk (n=17): 6MWD≤72% and CPI>41. 3-year mortality was % in the low risk group, % in the intermediate risk group and % in the high risk group (p<0.0001)(Suppl. Figure 5C ). The ROSE predicted 3-year mortality with a 67% sensitivity and a 91% specificity (Suppl. Figure 5D ). Table S1 . Modified MRC dyspnoea score (4). 
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